Xenotransplantation Organ Engineering Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Xenotransplantation Organ Engineering Market in 2026?

USD 823.5 million in 2026 and USD 1,967.5 million by 2036 at a 9.1% CAGR.

Demand for Xenotransplantation organ engineering is projected to push industry valuation from USD 823.5 million in 2026 to USD 1,967.5 million at 9.1% CAGR through 2036 reflecting regulated clinical investment. Transplant programs create commercial value through engineered donor organs that enter controlled recipient selection and intensive immunological surveillance. Investment across cross-species transplantation supports donor production systems that must deliver consistent organs with traceable genetic and microbiological records. UNOS reported in January 2026 that the United States completed 49,064 organ transplants during 2025. The same release counted more than 90,000 Americans on the kidney waiting list and confirmed persistent supply pressure. The continuing imbalance directs spending toward engineered supply, transplant-center readiness and monitoring tools that document rejection or infection rapidly. Associated transplant diagnostics capabilities also expand the addressable service layer through compatibility testing and lifelong recipient follow-up.

National adoption routes differ through regulatory control and transplant-center capacity rather than patient need alone. United States programs use FDA investigational pathways and concentrated surgical networks for early human studies. In contrast, Japan established a specific xenotransplantation risk-management framework under its regenerative medicine safety law in January 2025. The Japanese framework requires planned infection controls and formal review for every research or treatment program involving xenotransplantation. European systems place greater emphasis on coordinated organ preservation services and publicly managed transplant pathways. Germany and the UK also rely on national transplant coordination that supports standardized follow-up but slows fragmented commercial entry. South Korean programs operate through large research cohorts but face limited evidence for routine engineered-organ purchasing. Commercial entry therefore depends on regulatory sponsorship, specialist training and long-duration surveillance budgets in each country.

Summary of the Xenotransplantation Organ Engineering Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Organ scarcity creates measurable spending pressure through donor engineering, clinical validation and recipient surveillance across specialized transplant programs. Kidney waiting lists concentrate early commercial attention on therapies that could reduce prolonged dialysis exposure for carefully selected recipients. Clinical trial expansion requires validated source animals and reproducible organ production rather than isolated laboratory success across one transplant procedure. Infection monitoring adds recurring diagnostic and data-management needs throughout recipient follow-up and source-animal surveillance programs. Transplant centers require dedicated surgical coordination and intensive immunology support before engineered organs enter controlled clinical pathways.
Product and Segment View	The product architecture combines gene-edited donor organs with testing, preservation and clinical support needed for safe transplantation. Kidney is estimated to hold 39.1% of organ type in 2026, supported by its direct connection with end-stage renal disease treatment. Genetically engineered donor organs are projected to represent 41.1% of technology, attributable to compatibility edits that define the central product value. Organ failure treatment is forecast to account for 44.2% of application, driven by direct use among patients lacking suitable human organs. Transplant centers are estimated to hold 33.1% of end user, enabled by concentrated surgery and surveillance capabilities during initial adoption.
Geography and Growth Outlook	Country growth differs through trial regulation, transplant infrastructure and the funding available for prolonged clinical surveillance. Germany is projected at 11.0% CAGR through 2036, supported by established transplant centers and formal organ-allocation processes. South Korea is forecast at 10.4% CAGR from 2026 to 2036, enabled by research networks that support controlled clinical development. Japan is anticipated at 9.5% CAGR during the forecast period, reflecting a national framework for xenotransplantation risk management. United States and UK growth depends on trial access, center capacity and reimbursement for complex follow-up services.
Competitive Landscape	Competition centers on donor-organ design, clinical translation and workflow ownership rather than broad biotechnology scale alone. eGenesis develops gene-edited porcine kidneys and livers through clinical programs that require dedicated transplant-center partnerships. Revivicor and United Therapeutics combine source-pig engineering with investigational kidney and heart programs under FDA oversight. Makana Therapeutics, Recombinetics and Qihan Biotech focus on gene-editing platforms and source-animal development at different stages. OrganOx and XenoTherapeutics provide documented transplant workflow or adjacent xenograft capabilities rather than equivalent solid-organ platforms.
Analyst Perspective	Commercial decisions balance organ availability against uncertain clinical outcomes and unusually long obligations for surveillance and support. Program leaders should separate donor-organ manufacturing risk from surgical execution and post-transplant monitoring responsibilities across participating clinical institutions. Procurement models need clear funding for biosecure breeding, microbiological testing and rapid clinical escalation during adverse events. Expansion should follow documented center performance and recipient outcomes rather than broad assumptions about unmet medical need. - Anurag Sharma, Principal Consultant at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the xenotransplantation organ engineering market segmented?

The xenotransplantation organ engineering industry is segmented by organ type, technology, application, end user, and region.

Organ type separates kidney and heart programs from liver, lung and pancreas programs through distinct physiological and surgical requirements. Technology distinguishes genetically engineered donor organs from CRISPR-based editing, bioengineered organs and immune compatibility engineering. Application separates direct organ failure treatment from transplantation research and preclinical studies across regenerative medicine programs. End user distinguishes transplant centers and hospitals from biotechnology companies plus academic research institutes with different purchasing roles. Regional analysis compares clinical pathways and commercialization conditions across national healthcare systems with different approval and funding structures.

What supports demand for kidney xenotransplantation within the organ type category?

Kidney programs address a large treatment gap among patients who remain dependent on dialysis and face uncertain access to a human organ. The segment requires donor consistency, crossmatch testing and lifelong clinical surveillance rather than a stand-alone surgical product. The International Xenotransplantation Association published kidney guidance in April 2025 recommending triple-knockout donor pigs with added human transgenes and careful initial patient selection. Related stem cell therapy research can inform regenerative approaches but does not replace the need for a functional solid-organ graft.

• Kidney is projected to account for 39.1% of organ type in 2026, supported by the clear treatment pathway from dialysis to transplantation. The segment also offers measurable endpoints through filtration performance and dialysis independence across structured clinical follow-up at specialized transplant centers.
• Transplant nephrologists and surgical teams evaluate kidney xenografts through recipient selection, immunological compatibility and long-term infection monitoring. Adoption depends on repeatable source-organ quality and funded surveillance that remains available beyond the initial transplant procedure throughout lifelong recipient monitoring obligations at participating transplant centers.

How are genetically engineered donor organs positioned within the technology category?

Genetically engineered donor organs create value by reducing molecular incompatibilities that can trigger rejection, inflammation and abnormal growth. Development programs combine multiple gene deletions with human transgenes and source-animal pathogen controls across controlled breeding systems that document every donor generation. Commercial programs also require scalable CRISPR gene editing processes that preserve consistent donor characteristics across breeding generations during clinical production.

• Based on technology, genetically engineered donor organs are estimated to hold 41.1% in 2026, owing to their direct role in creating transplantable porcine organs. United Therapeutics reported in February 2025 that its UKidney trial used organs from pigs carrying ten gene edits.
• Biotechnology developers select multiplex editing platforms to coordinate immune compatibility with growth control and infectious-risk reduction. Purchasing interest strengthens through manufacturing records that connect each donor organ with verified genetics and biosecure source-animal management across repeated clinical production batches globally.

How does organ failure treatment shape the application category?

Organ failure treatment translates engineered organs from experimental platforms into patient-specific therapeutic programs with defined clinical endpoints. The application links donor production with surgical implantation and intensive care through long-term recipient monitoring requirements that extend across every participating clinical organization worldwide. Adjacent regenerative medicine technologies broaden scientific options but require separate evidence for functional replacement of a failing solid organ.

• By application, Organ failure treatment is forecast to represent 44.2% in 2026, driven by direct use among patients lacking timely human-organ access. Its commercial value depends on sustained graft function rather than technical completion of the transplant procedure alone.
• Transplant teams consider organ failure programs through disease severity, available alternatives and the recipient burden created by lifelong surveillance. eGenesis and OrganOx reported in April 2025 that FDA clearance covered a liver-support study enrolling up to twenty patients with acute-on-chronic liver failure.

What makes transplant centers central to the end user category?

Transplant centers coordinate recipient selection, organ preparation and emergency response across one highly controlled clinical pathway. United Therapeutics reported in May 2026 that its UHeart study would begin at one center and could add centers following review of early safety data. The structure resembles other advanced therapy trials that concentrate specialized teams during initial clinical adoption and require coordinated evidence management across participating sites.

• In 2026, transplant centers are set to account for 33.1%, enabled by concentrated surgery and transplant immunology capabilities. Independent hospitals without these services remain less suited to early engineered-organ programs and prolonged recipient surveillance across complex clinical protocols.
• Center directors require trained surgical teams and laboratory coverage that can identify rejection or zoonotic infection without delayed escalation. Commercial deployment therefore depends on funded protocols for organ logistics and intensive care plus lifelong patient monitoring across participating clinical sites.

What are the drivers, restraints, and opportunities in the xenotransplantation organ engineering market?

Organ scarcity supports clinical investment; infectious and immunological risks restrict routine adoption; integrated donor-production services create a credible development opening.

• Driver: Persistent organ shortages direct clinical research toward engineered donor supply that can enter repeatable transplant programs.
• Restraint: Infectious risk and immune rejection require biosecure production plus prolonged surveillance that increases program cost and accountability.
• Opportunity: Integrated manufacturing and transplant support can connect donor engineering with preservation, diagnostics and center-level clinical execution.

Clinical demand originates from patients who face long waits or poor access to suitable human organs. HRSA updated kidney allocation calculators in May 2025 using all deceased kidney donors recovered during 2024 and adult candidates listed at year-end. The allocation process shows how transplant programs already depend on structured donor and recipient risk information. Engineered-organ developers must fit comparable decision systems with evidence that supports patient selection and organ acceptance.

Infectious and immunological uncertainty creates a challenge for every engineered-organ program entering regulated clinical development. The International Xenotransplantation Association stated in 2025 that clinical use requires biosecure breeding and validated microbiological surveillance for source animals and recipients. Biosecurity and monitoring obligations extend operating costs beyond donor production and surgery across the complete recipient pathway. Routine adoption remains constrained until surveillance responsibilities and escalation procedures receive durable funding from clinical sponsors or healthcare systems.

Integrated clinical development provides a lucrative opportunity for companies that connect donor organs with transplant workflow and evidence systems. eGenesis reported in February 2025 that a second recipient received its genetically engineered porcine kidney at Massachusetts General Hospital and left dialysis. The transplant case creates operational learning for future programs rather than proof of routine commercial use across ordinary care settings. Developers can capture the opening through standardized gene therapy manufacturing records and center-specific protocols for monitoring and emergency response.

Which country CAGRs are profiled in the xenotransplantation organ engineering market?

Country	CAGR
USA	8.6%
UK	8.2%
Germany	11.0%
Japan	9.5%
South Korea	10.4%

How do country-level CAGRs compare in the xenotransplantation organ engineering market?

The country comparison spans 2.8 percentage points between Germany at 11.0% and the UK at 8.2%. Germany sits outside the central cluster through a 0.7-point separation from South Korea and a larger gap from Japan. South Korea and Japan remain within 0.8 point of each other and reflect comparable development momentum. The USA and UK form a compressed pair separated by 0.4 point across the complete assessment period. The spacing suggests different commercialization speeds without establishing current market size or installed-base leadership within any national system.

• Germany remains separated from the central forecast cluster through regulated transplant pathways and established hospital procurement structures.
• South Korea occupies the next forecast band through a coordinated research cohort that can support longitudinal transplant evidence.
• Japan remains close to South Korea through strict program governance and concentrated specialist transplant capacity.
• The USA combines private development activity with demanding payer review and lifetime monitoring obligations for participating clinical programs.
• The UK records a measured forecast position through public transplant procurement and regional organ-preservation capacity building.

Similar CAGRs can produce different entry conditions through regulation, center concentration and funding for long-duration surveillance. Commercial programs need country-specific partnerships rather than one deployment model across all five healthcare and regulatory systems. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States clinical activity is concentrated within FDA-regulated studies at major transplant centers with dedicated surgical and immunology teams. The United States xenotransplantation organ engineering market is projected to grow at 8.6% CAGR through 2036, supported by active kidney trial recruitment. ClinicalTrials.gov reported in March 2026 that the EXPAND xenokidney study was recruiting patients with end-stage renal disease under an FDA-regulated protocol. Multicenter trial infrastructure enables controlled expansion but lifetime monitoring creates a material financing and patient-retention burden. Commercial agreements require clear responsibility for source organs, investigational product logistics and long-term safety data.
• United Kingdom transplant purchasing operates through a public system that is building regional organ-assessment and perfusion capacity. Demand for xenotransplantation organ engineering in the UK is forecast to rise at 8.2% CAGR from 2026 to 2036, shaped by coordinated specialist services. NHS Blood and Transplant reported in March 2026 that the first of fifteen pilot assessment and recovery centers had opened across kidney, liver and lung programs. The network provides a practical enabler for organ assessment but routine engineered-organ procurement lacks an established public reimbursement pathway. Entrants need national clinical sponsorship and service agreements that fit centralized NHS governance plus regional transplant-center operations.
• Germany combines a nationwide transplant-center network with Eurotransplant allocation and formal national coordination for organ recovery. The German xenotransplantation organ engineering market is anticipated to advance at 11.0% CAGR through 2036, attributable to specialist capacity and preservation rules. The DSO reported in January 2026 that German centers transplanted 3,256 deceased-donor organs during 2025. The DSO year-end records also counted 8,199 people waiting for an organ across Germany during 2025. The established network enables controlled evaluation but hospital funding and national approval remain material barriers for investigational xenografts. Developers need German clinical partners that can integrate biosecure organ supply with Eurotransplant-era operating disciplines.
• Japan relies on centralized organ allocation and specialist hospitals that manage unusually long kidney waiting periods. Adoption of xenotransplantation organ engineering in Japan is estimated to expand at 9.5% CAGR between 2026 and 2036, enabled by concentrated transplant expertise and persistent waiting-list pressure. Japan Organ Transplant Network data updated in June 2026 listed 14,983 kidney candidates and 883 people waiting at least twenty years. The waiting burden creates a direct enabler for clinical interest but limited deceased donation and strict infection controls complicate early programs. Market entry requires local source-animal governance and Japanese-language protocols plus transplant-center training for prolonged recipient surveillance.
• South Korea supports transplant research through a national cohort that links clinical information across multiple organ programs and hospitals. South Korea’s xenotransplantation organ engineering outlook is estimated at 10.4% CAGR over the forecast period, linked to coordinated research infrastructure. The Korea National Institute of Health stated in July 2025 that eighty-three centers participated and the cohort targeted more than 2,000 new registrations annually. The network enables longitudinal evidence collection but no routine procurement channel exists for gene-edited porcine organs. Entrants require regulatory alignment and center-level training that connects donor records with infection surveillance and graft outcomes.

Who are the notable companies in the xenotransplantation organ engineering market?

eGenesis, Revivicor, United Therapeutics, Makana Therapeutics, Recombinetics, Qihan Biotech, OrganOx, and XenoTherapeutics are the notable companies profiled in this market.

The competitive structure separates clinical donor-organ developers from gene-editing platforms and transplant-workflow specialists with distinct roles. eGenesis and the United Therapeutics group operate kidney and heart clinical programs in the United States. Makana Therapeutics maintains a preclinical donor-organ program and Recombinetics develops broader organ-engineering capabilities through Regenevida. Qihan Biotech lists kidney and heart programs alongside lung, liver and intestine programs through multiplex gene editing. OrganOx supplies normothermic liver perfusion through a service model that supports transplant centers across established geographies. Adjacent 3D bioprinting technologies create a separate pathway through scaffold fabrication and cellular placement rather than gene-edited donor animals. Research on bioprinted organ transplants remains a distinct development route that cannot substitute for validated porcine organ supply during clinical programs.

• eGenesis develops EGEN-2784 kidneys and a liver-support program through active clinical pathways with defined transplant-center responsibilities. Revivicor supplies gene-edited source pigs within United Therapeutics programs covering UKidney, UThymoKidney and UHeart products.
• Makana Therapeutics applies source-animal engineering through a preclinical program focused on kidney, heart and islet applications. Recombinetics develops transplantable cells and organs through Regenevida while Qihan Biotech combines multiplex editing with immune shielding across several xenogeneic organ programs.
• OrganOx provides normothermic liver perfusion and clinical workflow support across established transplant geographies with dedicated technical services. XenoTherapeutics advances genetically engineered porcine skin through a recruiting Phase III study but remains adjacent to solid-organ transplantation.

Competitive Benchmarking: Xenotransplantation Organ Engineering Market

Company	Donor Organ Engineering	Clinical Translation	Workflow Support	Geographic Reach
eGenesis	High	High	Medium	United States
Revivicor	High	High	Medium	United States
United Therapeutics	High	High	High	United States
Makana Therapeutics	Medium	Low	Low	United States
Recombinetics	Medium	Low	Medium	North America
Qihan Biotech	Medium	Low	Low	China
OrganOx	Low	High	High	Global
XenoTherapeutics	Low	Medium	Medium	United States

Scoring basis: Donor Organ Engineering is High for proprietary solid-organ platforms in development, Medium for documented preclinical or enabling organ-engineering platforms and Low for adjacent xenograft or workflow products without solid-organ engineering. Clinical Translation is High for active human solid-organ trials, Medium for active human adjacent-xenograft studies and Low for documented preclinical programs without human enrollment. Workflow Support is High for dedicated transplant preservation or clinical infrastructure, Medium for protocol or manufacturing support and Low for product scopes limited to donor biology or one adjacent component.

Key Developments in the Xenotransplantation Organ Engineering Market

• In September 2025, eGenesis: FDA cleared the EGEN-2784 investigational new drug application for a Phase 1/2/3 kidney study in dialysis-dependent patients. The program linked a genetically engineered porcine kidney with defined recipient criteria and twenty-four-week efficacy assessment. The clearance established a formal clinical development route beyond expanded-access procedures and created defined evidence requirements for participating centers.
• In November 2025, United Therapeutics: The first participant received a UKidney in the EXPAND clinical trial at NYU Langone Health. The multicenter study began with six transplants across two centers and uses staged safety review before expansion. The development placed Revivicor source-organ engineering inside a registration-oriented clinical program with staged review and lifetime recipient monitoring.
• In September 2025, OrganOx: FDA approved operation of the metra normothermic liver perfusion system during air transport across the United States. OrganOx also announced twenty-four-hour device-to-donor support through Strata Critical Medical for transplant centers using the approved transport pathway. The approval broadens the service infrastructure available for complex liver programs that require extended preservation and functional assessment.
• In October 2025, Terumo completed its acquisition of all OrganOx shares and made OrganOx a wholly owned subsidiary. Terumo disclosed an approximate USD 1.5 billion transaction value and described organ transplantation as a new business sector. The completed transaction places OrganOx workflow technology inside a global device organization with broad service reach.

Key Players in the Xenotransplantation Organ Engineering Market

Clinical Donor Organ Developers

• eGenesis
• Revivicor
• United Therapeutics

Gene-Editing and Source-Animal Platforms

• Makana Therapeutics
• Recombinetics
• Qihan Biotech

Transplant Workflow and Adjacent Xenograft Providers

• OrganOx
• XenoTherapeutics

Xenotransplantation Organ Engineering Market - Report Scope

Coverage field	Report scope
Market breakdown	Organ type, technology, application, end user, and region.
Quantitative Units	USD million
Market Definition	Gene-edited or bioengineered donor organs and directly related clinical engineering services used for xenotransplantation development and transplantation workflows.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea.
Key Companies Profiled	eGenesis, Revivicor, United Therapeutics, Makana Therapeutics, Recombinetics, Qihan Biotech, OrganOx, and XenoTherapeutics.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Xenotransplantation Organ Engineering Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Xenotransplantation Organ Engineering Market by Segments

Xenotransplantation Organ Engineering Market segmented by Organ Type:

• Kidney
• Heart
• Liver
• Lung
• Pancreas

Xenotransplantation Organ Engineering Market segmented by Technology:

• Genetically Engineered Donor Organs
• CRISPR-based Gene Editing
• Bioengineered Organs
• Immune Compatibility Engineering

Xenotransplantation Organ Engineering Market segmented by Application:

• Organ Failure Treatment
• Transplantation Research
• Preclinical Studies
• Regenerative Medicine

Xenotransplantation Organ Engineering Market segmented by End User:

• Transplant Centers
• Hospitals
• Biotechnology Companies
• Academic & Research Institutes

Xenotransplantation Organ Engineering Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• United Network for Organ Sharing. (2026, January 28). USA surpasses 49,000 organ transplants while deceased organ donations dip.
• Ministry of Health, Labour and Welfare. (2025, January 17).[Implementation of xenotransplantation under the Act on the Safety of Regenerative Medicine].
• eGenesis. (2025, September 8). eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access Study.
• United Therapeutics Corporation. (2025, February 3). United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial.
• eGenesis. (2025, April 15). eGenesis and OrganOx Announce USA FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure.
• United Therapeutics Corporation. (2026, May 15). United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial.
• Health Resources and Services Administration. (2025, May 21). May 2025: Annual Kidney Allocation Calculator Updates.
• Fishman, J. A., Denner, J., & Scobie, L. (2025, April 8). International Xenotransplantation Association (IXA) Position Paper on Infectious Disease Considerations in Xenotransplantation. Xenotransplantation, 32(2), e70001.
• eGenesis. (2025, February 7). eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney.
• ClinicalTrials.gov. (2026, March 27). Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD (EXPAND).
• NHS Blood and Transplant. (2026, March 17). NHS starts machine preservation programme to enable more transplants.
• Deutsche Stiftung Organtransplantation. (2026, January 13). Organspendezahlen 2025 auf höchstem Stand seit 2012, dennoch weiterhin großer Bedarf [Organ donation figures in 2025 reach their highest level since 2012, but demand remains high].
• Japan Organ Transplant Network. (2026, June 30).[Number of people registered for kidney transplantation].
• Korea National Institute of Health. (2025, July 29). [Organ transplantation cohort].
• Meier, R. P. H., Pierson, R. N., Fishman, J. A., Buhler, L. H., Bottino, R., Ladowski, J. M., Ekser, B., Wolf, E., Brenner, P., Ierino, F., Mohiuddin, M. M., Cooper, D. K. C., & Hawthorne, W. J. (2025, April 8). International Xenotransplantation Association (IXA) Position Paper on Kidney Xenotransplantation. Xenotransplantation, 32(2), e70003.
• United Therapeutics Corporation. (2025, November 3). United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease.
• OrganOx. (2025, September 18). OrganOx metra® Receives FDA Approval for Operation During Air Transport, Expanding Access to Life-Saving Liver Perfusion Technology.
• Terumo Corporation. (2025, October 30). Terumo completes acquisition of OrganOx.
• United Therapeutics Corporation. (n.d.). United Therapeutics Pipeline.
• Makana Therapeutics. (2025, April 9). Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies.
• Recombinetics. (2025, March 13). Transplantable cells, tissues & organs for patients.
• ClinicalTrials.gov. (2025, April 2). Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting.

This bibliography presents the sources supporting retained article claims, while the full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the xenotransplantation organ engineering market in 2026 and 2036?
• Which clinical and supply pressures support investment in engineered donor organs?
• Why does kidney hold the main organ type share in 2026?
• How do genetically engineered donor organs shape technology spending?
• What limits routine clinical adoption across xenotransplantation programs?
• How do country growth rates compare across USA, UK, Germany, Japan, and South Korea?
• Which companies develop donor organs or support transplant workflows?
• What should transplant centers evaluate before joining an engineered-organ clinical program?
• How do infection surveillance and long-term follow-up affect commercial value?